NASDAQ · Financial Statements

Kyntra Bio, Inc. (KYNB) Financial Statements

$4.58 NASDAQ: KYNB Market Cap $18.55M

Kyntra Bio, Inc. most recently reported annual revenue of $6.0M, net profit of $183.0M. Revenue declined at an average annual rate of 49.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Kyntra Bio, Inc.: Revenue fell from $180.0M in 2016 to $6.0M in 2025, a change of -96.7% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -29.9% to -712.7%, a shift of -682.8 percentage points; the most recent year shows net profit of $183.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$180.0M$126.0M$213.0M$257.0M$176.0M$235.0M$141.0M$47.0M$30.0M$6.0M
Operating Expenses$233.0M$248.0M$300.0M$346.0M$368.0M$524.0M$442.0M$370.0M$180.0M$52.0M
Operating Profit$-54.0M$-123.0M$-87.0M$-89.0M$-192.0M$-289.0M$-301.0M$-323.0M$-150.0M$-46.0M
Operating Margin-29.9%-97.6%-40.7%-34.8%-108.8%-122.6%-213.9%-689.5%-507.8%-712.7%
Other Income$-8.0M$-3.0M$1.0M$13.0M$3.0M$-1.0M$8.0M$-1.0M$-3.0M$-12.0M
Interest$11.0M$10.0M$11.0M$3.0M$2.0M$1.0M$1.0M$8.0M$8.0M$9.0M
Depreciation$6.0M$6.0M$7.0M$21.0M$22.0M$15.0M$11.0M$10.0M$3.0M$1.0M
Profit Before Tax$-62.0M$-126.0M$-86.0M$-77.0M$-189.0M$-290.0M$-293.0M$-323.0M$-153.0M$-58.0M
Tax$110,000$-260,000$-350,000$-430,000$-190,000$-120,000$-120,000$80,000$180,000$150,000
Net Profit$-62.0M$-126.0M$-86.0M$-77.0M$-189.0M$-290.0M$-294.0M$-284.0M$-48.0M$183.0M
EPS$-0.98$-1.73$-1.03$-0.89$-2.11$-3.15$-3.15$-2.92$-0.48$45.37
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$40.0M$27.0M$25.0M$1.0M$46.0M$-123.0M$3.0M$1.0M$1.0M$1.0M$4.0M$-1.0M
Operating Expenses$104.0M$81.0M$75.0M$47.0M$63.0M$-32.0M$18.0M$13.0M$6.0M$15.0M$18.0M$16.0M
Operating Profit$-63.0M$-54.0M$-49.0M$-46.0M$-17.0M$-92.0M$-15.0M$-12.0M$-5.0M$-14.0M$-14.0M$-18.0M
Operating Margin-158.2%-199.7%-193.9%-4650.1%-36.2%74.4%-540.1%-864.9%-499.1%-1102.0%-369.7%1192.3%
Interest$5.0M$5.0M$2.0M$2.0M$5.0M$0$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax$-64.0M$-56.0M$-49.0M$-47.0M$-17.0M$-88.0M$-17.0M$-14.0M$-13.0M$-15.0M$-15.0M$12.0M
Tax$-130,000$-140,000$-10,000$590,000$-70,000$60,000$-10,000$670,000$0$0$0$-10,000
Net Profit$-64.0M$-56.0M$-33.0M$-16.0M$-17.0M$18.0M$5.0M$-8.0M$148.0M$38.0M$-15.0M$12.0M
EPS$-0.65$-0.57$-0.33$-3.89$-4.25$4.50$0.05$-1.88$49.61$9.38$-3.76$2.96

Over the 10 years reported for Kyntra Bio, Inc., borrowings decreased from $97.0M in 2016 to $0 in 2025, cash stood at $48.0M in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 3.41 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$470.0M$899.0M$881.0M$857.0M$827.0M$774.0M$610.0M$424.0M$215.0M$120.0M
Current Assets$267.0M$749.0M$690.0M$702.0M$755.0M$474.0M$493.0M$332.0M$197.0M$99.0M
Cash$174.0M$674.0M$89.0M$126.0M$678.0M$171.0M$156.0M$114.0M$50.0M$48.0M
Inventory$0$0$0$7.0M$17.0M$31.0M$40.0M$42.0M$3.0M$4.0M
Receivables$10.0M$8.0M$64.0M$154.0M$42.0M$25.0M$16.0M$41.0M$29.0M$4.0M
Fixed Assets$124.0M$129.0M$127.0M$82.0M$63.0M$119.0M$100.0M$81.0M$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$150.0M$73.0M$588.0M$469.0M$11.0M$406.0M$276.0M$127.0M$0$61.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$294.0M$316.0M$352.0M$322.0M$385.0M$545.0M$612.0M$586.0M$398.0M$115.0M
Current Liabilities$65.0M$77.0M$89.0M$103.0M$163.0M$225.0M$274.0M$218.0M$133.0M$29.0M
Borrowings$97.0M$98.0M$97.0M$52.0M$40.0M$100.0M$90.0M$170.0M$73.0M$0
Other Liabilities$197.0M$218.0M$255.0M$270.0M$346.0M$445.0M$522.0M$415.0M$325.0M$115.0M
Equity$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Reserves$156.0M$563.0M$509.0M$516.0M$422.0M$209.0M$-21.0M$-204.0M$-226.0M$-30.0M

For Kyntra Bio, Inc., operating cash flow was positive in 2 of 10 reported years; free cash flow in the latest year was negative at $5.0M; free cash flow was positive in 2 of 10 years; financing activities used $5.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$7.0M$-67.0M$-76.0M$-79.0M$82.0M$-82.0M$-146.0M$-315.0M$-138.0M$-5.0M
Investing Cash Flow$5.0M$61.0M$-530.0M$114.0M$448.0M$-457.0M$50.0M$151.0M$126.0M$35.0M
Financing Cash Flow$-3.0M$-9.0M$-16.0M$-13.0M$-11.0M$-7.0M$43.0M$1.0M$2.0M$-5.0M
Net Cash Flow$20.0M$500.0M$-584.0M$37.0M$552.0M$-507.0M$-16.0M$-42.0M$-12.0M$-54.0M
Free Cash Flow$6.0M$-75.0M$-84.0M$-84.0M$78.0M$-112.0M$-185.0M$-318.0M$-138.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.33
FCF Yield-193.82%
Quick Ratio2.59
Interest Coverage-5.47
Return 1Y0.68%
Return 3Y-88.57%
Return 5Y-97.95%

Kyntra Bio, Inc. (KYNB) financials — frequently asked questions

What is Kyntra Bio, Inc.'s annual revenue?

Kyntra Bio, Inc. (KYNB) reported annual revenue of $6.0M in its most recent fiscal year.

What is Kyntra Bio, Inc.'s net profit?

Kyntra Bio, Inc. (KYNB) reported net profit of $183.0M in its most recent fiscal year.

What is KYNB EV/EBITDA?

Kyntra Bio, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.33.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
KYNB Overview KYNB Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.